The global transdermal drug delivery systems market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.
The transdermal drug delivery system (TDDS) is an alternative system of delivering drugs through the skin for systemic distribution. It is used as an alternative to oral intravascular, subcutaneous, and transmucosal routes. TDDS supports both chronic and acute diseases as well as cosmetic procedures as it delivers biologically active agents, such as drugs and cosmeceuticals, through the skin. It offers a controlled release of drugs, which reduces the first-pass metabolism effects, lessens the side effects, and improves the efficacy of the dosage by enabling a steady blood drug profile throughout the treatment.
The global transdermal drug delivery systems market is primarily driven by the growing instances of chronic disorders that cannot be treated through conventional drug delivery systems, such as oral drugs. Patients with long-term ailments, such as diabetes, are shifting toward self-administration of medicine. As a result, there has been an introduction of adhesive skin patches to administer the daily course of medication without the pain. This has encouraged patients and physicians to prefer pain-free drug delivery systems. Besides this, the wide adoption of third-generation transdermal drug delivery systems like iontophoresis promotes self-reliance in patients since it reduces frequent visits to hospitals and lessens the cumulative treatment costs. Furthermore, technological advancements, such as the inclusion of microneedles, modifications in transdermal patch designs and the incorporation of pressure-sensitive adhesives and permeation enhancers, are providing vast opportunities to manufacturers.
IMARC Group provides an analysis of the key trends in each sub-segment of the global transdermal drug delivery systems market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, technology and application.
Breakup by Technology:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Acrux Limited, Boehringer Ingelheim International GmbH, Hisamitsu Pharmaceutical Co. Inc., Lavipharm S.A., LEAD CHEMICAL Co. Ltd., Luye Pharma Group, Nutriband Inc. and Viatris Inc.
|Base Year of the Analysis||2020|
|Segment Coverage||Technology, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3M Company, Acrux Limited, Boehringer Ingelheim International GmbH, Hisamitsu Pharmaceutical Co. Inc., Lavipharm S.A., LEAD CHEMICAL Co. Ltd., Luye Pharma Group, Nutriband Inc. and Viatris Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at